Japanese Astronaut to be 1st Non-American to Set Foot on Moon

MARTIN, OHIO - APRIL 08: The moon passes in front of the sun during a solar eclipse on April 08, 2024 in Martin Ohio. Gregory Shamus/Getty Images/AFP
MARTIN, OHIO - APRIL 08: The moon passes in front of the sun during a solar eclipse on April 08, 2024 in Martin Ohio. Gregory Shamus/Getty Images/AFP
TT

Japanese Astronaut to be 1st Non-American to Set Foot on Moon

MARTIN, OHIO - APRIL 08: The moon passes in front of the sun during a solar eclipse on April 08, 2024 in Martin Ohio. Gregory Shamus/Getty Images/AFP
MARTIN, OHIO - APRIL 08: The moon passes in front of the sun during a solar eclipse on April 08, 2024 in Martin Ohio. Gregory Shamus/Getty Images/AFP

A lucky Japanese astronaut will become the first non-American to set foot on the Moon during one of NASA's upcoming Artemis missions, US President Joe Biden announced Wednesday.

The offer to Japan -- an opportunity many nations have long dreamed of -- came as part of Prime Minister Fumio Kishida's state visit, and as Washington seeks to strengthen ties with its key Asian ally.

"Two Japanese astronauts will join future American missions, and one will become the first non-American ever to land on the Moon," Biden said in a press conference with Kishida, according to Agence France Presse.

Kishida hailed the announcement as a "huge achievement" and announced that Japan would in return supply a rover for the program.

NASA's Artemis program seeks to return humans to the Moon for the first time in over 50 years, and to build a sustained lunar presence ahead of potential missions to Mars.

Between 1969 and 1972, the US Apollo program saw 12 Americans -- all white men -- walk on the Moon.

NASA previously announced that the Artemis program would see the first woman and the first person of color land on the Moon.

"America will no longer walk on the Moon alone," NASA chief Bill Nelson said in a video published on social media.

"Diplomacy is good for discovery. And discovery is good for diplomacy," he added.

The first mission to take astronauts to the lunar surface, Artemis 3, is planned for 2026. China meanwhile has said it seeks to put humans on the Moon by 2030.

Japan's space agency JAXA is "extremely happy" about the announcement, a spokesman told AFP.

"We will do our best to implement the agreement," including developing the rover for the program, he said.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”